Source comparison
MOTS-c Safety Studies: Comparison of Peptide Safety Profiles
MOTS-c <8% Injection-site reactions (mild erythema, tenderness) None reported 12 weeks Cleanest short-term profile; no systemic toxicity signals; long-term data absent BPC-157 12–18% GI discomfort, mild nausea None in controlled trials 8 weeks Well-tolerated b
This comparison does not assign a generated winner or score.
- MOTS-c
- <8%
- Injection-site reactions (mild erythema, tenderness)
- None reported
- 12 weeks
- Cleanest short-term profile; no systemic toxicity signals; long-term data absent
- BPC-157
- 12–18%
- GI discomfort, mild nausea
- None in controlled trials
- 8 weeks
- Well-tolerated but more GI side effects than MOTS-c
- Thymosin Beta-4
- 10–15%
- Injection-site pain, transient fatigue
- 16 weeks
- Similar tolerability; longer safety dataset
- GHK-Cu
- 15–22%
- Skin irritation (topical), injection-site reactions (SC)
- Rare allergic reactions
- 24 weeks
- Higher local reaction rate; more dermatological use data
- Selank
- 8–12%
- Mild sedation, transient drowsiness
- Comparable safety; CNS-active so different mechanism
- MOTS-c stands out for the absence of systemic adverse events. Other mitochondrial-targeted peptides. Humanin, SS-31. Show similar profiles, but published human data for those compounds remains even more limited than MOTS-c.